

Special Issue

Novel Therapies of Salivary Gland Cancer

Message from the Guest Editor

Salivary gland cancer presents significant challenges due to its diverse histological subtypes; variable clinical behavior; and, like other head-and-neck cancer subtypes, limited treatment options. Despite advancements in surgery, radiation therapy, and chemotherapy, the prognosis for patients with advanced or recurrent disease remains poor, highlighting the urgent need for novel therapeutic approaches. This Special Issue aims to support publishing manuscripts which provide emerging therapies for salivary gland cancer, encompassing both conventional modalities and cutting-edge advancements in the field. By elucidating the current landscape of therapeutic options and highlighting promising avenues for future research, this Special Issue seeks to contribute to the ongoing efforts made to improve outcomes and quality of life for patients with salivary gland cancer.

Guest Editor

Dr. Moritz Meyer

Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen, Germany

Deadline for manuscript submissions

closed (10 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/202535

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)